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In its unique position at the interface between blood and
tissues, vascular endothelium participates in critical homeo-
static functions, including the regulation of transcapillary per-
meability, the maintenance of a non-thrombogenic surface, the
modulation of vascular tone and reactivity, the control of
proliferation of vascular hematopoietic cells, and the modula-
tion of immune function [1, 21. Recent studies have also shown
that endothelial cells play active roles in all phases of immuno-
logic and nonimmunologic inflammation, and that in these roles
they serve not only as targets which undergo cell injury, but
respond by exhibiting specific alterations in their normal con-
stitutive properties, or by acquiring new functions [3, 41. Much
of the new information regarding endothelial function in inflam-
mation has come from studies of the effect of cytokines on
endothelial cells in culture. Although few of these studies have
been performed on renal endothelium, which has been difficult
to culture, there is no a priori reason why the cytokine-induced
effects are not relevant to the kidney. In this paper, we will
review the effects of well characterized cytokines on endothe-
hal cells in vitro, examine the role of endothelial activation in
several clinical settings in vivo, and emphasize those reactions
that may be particularly relevant to renal injury.
Effects of cytokines in vitro
The recent purification of a number of cytokines and their
expression as recombinant gene products has permitted a
detailed examination of their effects on a variety of endothelial
functions.
Interleukin 1 (IL-I), tumor necrosis factor (TNF),
lymphotoxin (LT)
IL-i and TNF are polypeptide products of activated macro-
phages which were originally defined by their biological activ-
ities: IL-i as a co-mitogen for murine thymocytes stimulated
with concanavalin-A, and TNF by its tumoricidal activity in
culture. Two separate IL-l gene products have been cloned,
IL-i a and IL-l /3 [5]. These polypeptides show limited struc-
tural homology and exhibit identical biological activities. The
TNF gene has been cloned, sequenced and expressed, and has
virtually no homology to IL-l [6]. IL-l and TNF, however, are
pleiotropic mediators which share numerous inflammatory
properties. Lymphotoxin is a polypeptide secreted by activated
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T-lymphocytes, and has the same tumor killing activities as
TNF [7, 8] It has structural homologies to TNF and competes
with TNF for binding to the same cell surface receptor [9].
These three cytokines have many similar effects on cultured
endothelial cells (Table 1). The first studies to be reported were
concerned with the effects of IL-l on the modulation of endo-
thelial cell coagulant properties. Bevilacqua et al showed that
IL-l markedly increases tissue factor-like procoagulant activity
(PCA) in cultured human umbilical and saphenous vein endo-
thelial cells [10]. Increased procoagulant activity was transient,
being maximal at four to eight hours after cytokine treatment,
and, most importantly, was inhibited by actinomycin-D and
cycloheximide, indicating a requirement for RNA and protein
synthesis, respectively. It was subsequently shown that TNF
has the same effect [11, 12]. In addition, IL- 1 and TNF decrease
endothelial surface thrombomodulin [11, 13], thus markedly
inhibiting the anti-coagulant effects of protein S and protein C,
increase the secretion of the inhibitor of tissue plasminogen
activator, and possibly decrease the secretion of tissue plasmin-
ogen activator itself [14—17]. All of these effects tend to tip the
balance of the coagulant/anti-coagulant molecules on the sur-
face of endothelium towards fibrin deposition and intra-vascular
coagulation (Fig. 1). Indeed, IL-l infusions in rabbits cause
fibrin deposition on an apparently intact endothelium in vivo
[13].
The second major effect of IL-i and TNF on endothelium is
the stimulation of increased surface adhesivity for polymorpho-
nuclear leukocytes, monocytes, lymphocytes and leukocyte
cell lines [18—221. These effects of IL-l and TNF are also
blocked by RNA and protein synthesis inhibitors [19]. The
effects peak at four to six hours and decline by 24 hours, but for
neutrophils and monocytes, adhesion remains above control
values at 24 hours. Such stimulated adhesion is not affected by
cyclooxygenase inhibitors. Subsequently, the development of
monoclonal antibodies against IL-i stimulated endothelial cells
led to the identification of an endothehial leukocyte adhesion
molecule (ELAM- 1) which inhibits binding of polymorphonu-
clear leukocytes to IL-i, TNF- or LT-treated endothehial cells,
during maximal adhesion at four to six hours. ELAM-l is
identified by two monoclonal antibodies, H18/7 [23] and H4/18
[24], which, as will be described later, are also useful markers
for endothehial activation in vivo. The ligand for ELAM-i on
neutrophils has not been identified, but it does not appear to be
a component of the leukocyte adhesion molecules of the CD1 1/
18 complex (the CD1 1/18 complex describes three separate cell
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surface molecules that are heterodimers composed of individual
a chains but a /3 chain common to all three; the individual
molecules are called LFA-l, Mac-i and p150,95) [251.
In addition to inducing ELAM-1 expression on endothelial
cells, IL-i, TNF and LT also stimulate increased surface
expression of ICAM-i (intracellular adhesion molecule-i), an
adhesion molecule described by Dustin and his collaborators on
the surface of fibroblasts, lymphocytes and normal edothelium
[26]. The increased expression of ICAM-1 induced by the
cytokines is maximal at 24 hours (whereas it peaks at 4 to 6
hours for ELAM-l), and it is sustained as long as the cytokines
remain in the culture medium [27—301. Marlin and Springer have
recently provided evidence that ICAM-l is a ligand for LFA-I
molecule of the CD11/18 complex [281, and that it also serves as
an endothelial adhesion molecule to bind lymphocytes and
possibly monocytes and polymorphonuclear leukocytes to
endothelium [29] It should be stressed that increased expression
of ICAM-l can also be induced by y interferon (IFN-y) and on
other cell types, including dermal fibroblasts and lymphoid
cells, whereas ELAM-1 expression is not affected by IFN-y and
is endothelium specific [251. In contrast to the endothelial-
dependent effects of cytokines described above, certain stimuli,
such as complement components and phorbolesters, increase
leukocyte adhesion to endothelium by acting principally on
leukocytes [31, 32]. These effects are mediated through the
leukocyte adhesion molecules of the CDI 1/18 complex [33—35]
(LFA-l, Mac-i, p150,95), since it is inhibited by antibodies to
the 13 chain or individual a chains of the complex. TNF acts
both on the leukocytes and endothelium. It induces a leukocyte-
dependent immediate increase in adhesivity, which can be
blocked by antibodies to the CD! 1/18 complex [21], and an
endothelial dependent effect at four to six hours, which can be
inhibited by antibodies to ELAM-l [22].
IL- 1, TNF and LT can also alter endothelial cell morphology
and cytoskeletal organization. These effects are slower, taking
three to six days to become apparent and result in conversion of
the polygonal epithelial-like shape of endothelial cells to a
spindle shaped organization consisting of overlapping, elon-
gated cells [36]. There is rearrangement of actin filaments from
dense peripheral bands to longitudinal streaks, and loss of
fibronectin in the basement membrane. These changes are very
similar to those which occur with IFN-y. Combinations of IL-i
or TNF plus IFN-'y appear to synergize in their morphological
effects, and at optimal concentrations, combining the mediators
results in unique morphological changes characterized by
plump, retracting cells and intercellular gaps [36]. All these
morphological changes are reversible.
There are numerous other endothelial effects induced by
IL-I, TNF and LT which are listed in Table 1 [371. These
include the release of prostacyclin, platelet-derived growth
factor and colony-stimulating factors [38]. Of interest is that the
endothelium itself is capable of IL-i synthesis, when stimulated
by IL-l, TNF, LT and endotoxin [39—42]. Most IL-l synthe-
sized by endothelial cells is not secreted but rather remains
associated with the plasma membrane (membrane IL-l) [43],
and it has been suggested that membrane IL- 1 may be optimally
positioned to act as a co-stimulator of T cell activation, as the
relevant MHC antigens are co-expressed with IL-i on the cell
surface [44]. It should be stressed that the amount of secreted
IL-i induced by endothelium is very small compared to mac-
rophage IL-i and thus, its role as a pro-coagulative or pro-
inflammatory stimulus in vivo is uncertain.
Most of the effects of IL-l, TNF and LT described above
render endothelial cells capable of actively influencing the
evolution of the inflammatory response, but are in themselves
not injurious to the endothelium. There is evidence, however,
that cytokine-treated endothelial cells may be more susceptible
to injury. For example, Varani et al have shown that pre-
treatment of rat pulmonary artery endothelial cells with TNF or
IL-i increases in a time- and dose-dependent manner their
sensitivity to killing by neutrophils stimulated with phorbol
esters or C5a [45]. Whether this is true for human endothelium
is uncertain, but it is likely that in vivo endothelial activation
and endothelial injury often co-exist.
Do any of the IL-l/TNF endothelial cell effects described in
endothelial cultures occur in the kidney? As mentioned earlier,
there have been few similar studies with cultured renal endo-
thelium. Daniel et al found that treatment of a preparation of
renal cortical endothelial cells with thrombin stimulated secre-
tion of platelet derived growth factor [46]. IL-i was not effec-
tive in this assay but Hajjar et al [38] found that TNF did
stimulate PDGF secretion by non-renal endothelial cells, Ber-
tani et al recently reported that intravenous infusions of TNF in
rabbits caused intraglomerular leukocyte and serum platelet
aggregation and infiltration, endothelial cell "damage" and
rising creatinines [18]. Hancock and Cotran treated isolated
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Fig. 1. Pro- and anti-coagulant properties of vascular endothelium.
Most of the effects of IL-I, TNF and LT tip the balance towards
intravascular coagulation.
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Fig. 2. Glomerulus from a baboon in septic shock
induced by E-coli, stained by the immunoperoxidase
technique for ELAM-1, using H4-18 as antibody.
Note staining of glomerular endothelial cells. Similar
endothelial staining was present in endothelium from
other organs.
Table 2. Principal endothelial effects of interferons
Stimulation of class I MHC antigens IFN y,f3,a
Stimulation of class II MHC antigens IFN y
Increased ICAM- 1 and lymphocyte binding IFN y
Morphological changes IFN y
ical staining the induction of ELAM-l expression in glomerular
endothelium, after four to six hours [47]. In collaboration with
Drs. Tracey, Cerami and their associates, we examined kidneys
from baboons perfused experimentally with live E. coli to
induce septic shock. In this model, the development of septic
shock can be inhibited by pretreating the animals with antibod-
ies to TNF [48]. Using immunocytochemistry and H4/l8 anti-
body we found striking staining of glomerular endothelial cells
for the IL-l/TNF specific inducible molecule, ELAM-l, in
animals undergoing septic shock (Fig. 2). Staining was associ-
ated with adherent neutrophils. It is thus likely that cytokine-
induced events reported in other endothelia also affect endo-
thelial cells in the kidney.
ylnterferon (IFN-y)
IFN-y has profound effects on endothelial cells in culture
(Table 2). Indeed, the first clear-cut endothelial effect of a
cytokine to be discovered was the induction of Class II MHC
antigen synthesis and surface expression by cultured human
umbilical vein and foreskin microvascular endothelial cells [49].
Expression is first detected about six to eight hours after IFN-y
exposure and reaches a plateau after four to six days. As long as
the IFN-y remains in culture, the effect persists and is associ-
ated with expression of all known class II antigens (HLA-DR,
DP, and DQ) [50]. IFN-y also increases the expression of Class
I (HLA-A,B,C) antigens, which are present on endothelium
under normal conditions. Increased Class I antigen is not
specific for IFN-y, being also induced by IFN-a, IFN-/3, TNF
[51] and LT [30]. Class I MHC antigens are important in
recognition of foreign antigens by cytolytic T-lymphocytes, and
Class II MHC antigens are necessary for presentation of antigen
to helper T cells. Pober and his associates showed that IFN-y-
treated endothelial cells are capable of accessory cell function.
The expression of Class II MHC by IFN-y is necessary (but
insufficient) to permit allogeneic endothelial cells to activate
T-lymphocytes [52]. IFN-y also causes increased expression of
ICAM- 1 with a time course resembling that of Class II MHC
modulation. In addition to its effect on antigen expression,
IFN-y causes a remarkable reorganization in endothelial cell
morphology: two to three days after addition of IFN-y, the
strictly contact-inhibited and normally polygonal endothelial
cells become markedly elongated, overlap extensively, and
exhibit reorganization of the actin cytoskeletons.
In summary, cytokines are important modulators of endothe-
hal cell phenotype in vitro. IL-l, TNF and LT have profound
influences on endothehial cell surface thrombogenicity and
leukocyte adhesivity and have a number of other pro-inflam-
matory properties. The most important endothelial effects of
IFN-y, are the induction of Class I and Class II antigens and the
characteristic morphological changes. TNF and LT, and IFN-/3
also have effects on endothelial cell Class I surface expression
and endothelial cell shape, and in certain instances, these
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We have referred to the alterations in structure and function
induced in endothelium by cytokines as "endothelial activa-
tion" [37], akin to the alterations which occur in activated
lymphocytes and macrophages. Although the concept of endo-
thelial activation now assumes a more precise cell biological
meaning, the term was used over 20 years ago to describe the
morphological changes in the endothelium in delayed hypersen-
sitivity reactions [54]. The morphological alterations include
hypertrophy of endothelial cells, which acquired a plump,
cuboidal appearance and protrude into the lumen and a marked
increase in biosynthetic organelles as seen by electron micros-
copy [55]. A functional connotation was implied, but could not
be demonstrated. We will now turn to present evidence that
such endothelial activation, largely induced by cytokines, oc-
curs in vivo and may play a role in immune and vascular injury.
Endothelial activation in vivo
That endothelial activation, recapitulating some of the in
vitro inducible endothelial cell effects occurs in vivo was
suggested by several observations. An early study showed that
intradermal injections of crude lymphokine-containing superna-
tants into the skin of cancer patients resulted in vascular
changes similar to those seen in delayed hypersensitivity reac-
tions [56]. Infusions of IL-l or TNF in rabbits [17] and rats [571
cause fibrin deposition in the endothelium [17] and leukocyte
aggregation [57], and replace the need for a second injection of
endotoxin in the localized Schwarzmann phenomenon. Class II
antigens appear on endothelium early in experimental delayed
hypersensitivity reactions [58]. In our laboratory, we have
addressed the question of the occurrence of endothelial activa-
tion in vivo by two approaches: in the first, we examined human
tissues by immunocytochemical techniques for the presence of
endothelial antigens that are either induced or enhanced by
cytokines in vitro. The three most useful antigens are: (1)
ELAM-1 [23], detected by monoclonal antibodies H4/l8 [24]
and Hl817 [23]. ELAM-1 is absent in normal endothelium and
thus any detectible amounts uncovered by cytochemical meth-
ods reflects activation; (2) ICAM-l [26], present in normal
endothelium but markedly enhanced in vitro by IFN-y, LT,
TNF and IL-l, and detected by antibody RR1I1 [27]; and (3) the
HLA/DQ or HLAIDP molecules which are markedly enhanced
by IFN-y, and can be detected by antibodies Leu-lO or B7/21,
respectively. We first examined elicited delayed hypersensitiv-
ity reactions in human skin and found that postcapillary yen-
ules, at the height of the reaction, showed prominent ELAM-l
expression [14] and significant increases in both ICAM-l and
HLA/DQ (unpublished observations). We then examined a
large series of inflammatory, neoplastic and immune reactions
in human lymph nodes and skin, and found prominent and
frequent endothelial staining in cases of acute granulomatous
lymphadenitis, Hodgkin's lymphoma, T cell lymphoma and in
inflammatory and immunological reactions of the skin associ-
ated with an active inflammatory infiltrate [59, 60] (Table 3).
This overview of clinical material indicated that endothelial
activation occurs regularly in settings of inflammation associ-
ated with activated lymphocytes and monocytes. Indeed, in the
case of delayed hypersensitivity reactions, it may be suggested
that the alterations in structure and function induced in endo-
thelium by specific lymphokines and monokines are the causes
of the vascular changes previously described in these reactions,












including increased permeability, increased leukocyte adhe-
sion, increased replication, and endothelial hypertrophy.
The second approach was to study the effects upon endothe-
hal function and antigen expression of intradermal injections of
recombinant cytokines, alone or in combination, in the baboon
(Papio anubis). The baboon was chosen because our immuno-
cytochemical reagents developed in humans crossreact with
baboon tissues, and because human cytokines and antibodies to
cytokines are biologically active in baboons. The results thus-
far, reported by Munro, Pober and Cotran [61] indicate that
IFN-y and TNF cause induction or increased expression of
ELAM- 1, ICAM- 1 and HLA-DP in microvascular endothelium
in vivo in a pattern which resembles that which occurs in vitro.
Further, both neutrophil and mononuclear cell infiltration result
from these injections in a time sequence and pattern compatible
with the effects of these cytokines on endothelial adhesion in
vitro. These studies leave little doubt that the cytokine effects
uncovered from culture studies will prove to have relevance in
inflammation and immunity in experimental models and in
human inflammatory reactions.
Role of endothelial activation in immune and vascular injury
Besides the role of endothelial activation in inflammatory
reactions, there is increasing evidence that the process may
contribute, under certain circumstances, to actual vascular
injury. The evidence derives from three sets of studies.
The vascular leak syndrotne after IL-2 therapy
IL-2 therapy, usually before the administration of lympho-
kine activated cells, is an experimental cancer treatment which
is successful in retarding tumor growth in a proportion of
patients, but is associated with a number of toxic complications
[62]. The most important side effect is the vascular leak
syndrome, characterized by generalized edema, and occasion-
ally, erythromatous skin lesions. In collaboration with Dr.
Michael Lotze and his associates at the National Cancer
Institute, we have recently examined biopsies from such cancer
patients, examined before and one to five days after adminis-
tration of IL-2 [63]. It was found that endothelial cells in
pre-IL-2 biopsies, as expected, did not exhibit ELAM-1 endo-
thelial staining, but post-treatment biopsies invariably had
ELAM-1 on the endothelium. There was also increased expres-
sion of ICAM-l and HLA-DQ in biopsies studied after IL-2
treatment. IL-2 itself does not stimulate the expression of these
molecules in endothelial cultures in vitro, but it does stimulate
the synthesis and release of IFN-y, TNF, and LT from lym-
phoid cells [62, 64], suggesting that the IL-2 effect is induced by
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endogenous production of cytokines capable of activating endo-
thelium. Because activation is associated with increased vascu-
lar permeability in delayed hypersensitivity reactions, we sug-
gest that it may well play a role in the vascular leak syndrome
after IL-2 therapy.
Endothelial activation in Kawasaki's disease
Kawasaki's disease is a childhood disease associated with
fever, mucocutaneous manifestations and a panvasculitis of
unknown etiology. The disease is characterized by immunoreg-
ulatory disturbances, including increased T cell and polyclonal
B-cell activation. Interestingly, sera from patients in the acute
phase of Kawasaki's disease possess antibodies that cause lysis
of activated, but not normal, cultured human endothelial cells
[65, 66]. One type of antibody lyses IL-i and TNF-treated
endothelial cells, and the other lyses IFN-y-treated endothelial
cells. The time-course of induction of the target antigens is
similar to the time-course of maximal cytokine stimulation, that
is, four to six hours for IL-l or TNF-treated endothelial cells
and three to four days for IFN-y exposed cells. Sera from
convalescent patients, normal controls, or patients with fever,
fail to exhibit lysis of cytokine treated cells. In recent unpub-
lished studies done in collaboration with Dr. Leung, we have
detected activation antigens immunocytochemically in endothe-
hal cells of skin biopsies in acute Kawasaki's syndrome. While
the precise sequence of events leading to endothelial activation
and the formation of the lytic antibodies and their precise role in
the syndrome is unknown, it is tempting to speculate that the
enhanced T-cell activity present in these patients results in the
elaboration of cytokines that activate endothelium and induce
new surface antigens. The latter, in turn, elicit an antibody
response that results in endothelial cell lysis and possibly,
eventual vascular injury. In this instance, therefore, endothelial
activation may play a role in the subsequent development of
vascular injury.
Hemolytic uremic syndrome
Leung and his associates also recently found that sera from
patients with the acute hemolytic uremic syndrome (HUS)
contain complement fixing antibodies which lyse cultured hu-
man umbilical vein endothelial cells, but remarkably, not endo-
thelial cells that have been treated with IFN-y [67]. In contrast,
only three of the five adult patients with acute non-relapsing
thrombotic thrombocytopenic purpura (TTP) had lytic anti-
endothelial antibodies, and only one of these recognized an
antigen lost upon IFN-y treatment. The nature of the endothe-
hal cell surface antigen recognized by HUS sera is unknown.
The fact that HUS sera lyses resting endothelial cells but not
those stimulated with IFN-y, raises the possibility that the
cytokine induces either a specific loss of an antigen, or altera-
tion in structure or accessibility of endothelial cell surface
molecules. In addition, the patterns of reactivity of circulating
anti-endothelial cell antibodies may serve to distinguish HUS
from the acute, non-relapsing form of TTP.
In summary, there is now considerable evidence that many of
the endothelial effects induced by cytokines in vitro occur in
vivo. There is also evidence that the process of endothelial
activation may, under certain circumstances, lead to vascular
and immune injury. The realization that endothelial cells are
active participants in inflammatory reactions, and that endothe-
hal activation may underlie certain immune-mediated patho-
logic processes should provide fruitful approaches for investi-
gation of the pathogenesis of heretofore poorly understood
disorders—in the kidney and elsewhere.
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